OM336 not checked

Lakefront Biotherapeutics West LLC

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
3 active
3 in total · 2 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“OM336 is an engineered bispecific antibody directed against BCMA and CD3”In the company’s words, NCT07083960 on ClinicalTrials.gov
Tested for
AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia, ITP - Immune Thrombocytopenia, Sjogrens Disease, Idiopathic Inflammatory Myopathy (IIM)
Main trialPhase 1
“An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.”In the company’s words, NCT07083960 on ClinicalTrials.gov

Other drugs for AIHA - Cold Autoimmune Hemolytic Anemia

All 8 drugs for AIHA - Cold Autoimmune Hemolytic Anemia

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 1Recruiting Dec 2026 OM336 in Autoimmune Cytopenias
Phase 1Recruiting Jun 2027 OM336 in Seropositive Autoimmune Diseases
Phase 2Authorised not given An Open-Label Phase IIa Trial Exploring the Safety, Tolerability, and Efficacy of the T Cell Engager OM336 for Desensitization of Kidney Transplant Candidates
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow OM336

Following is part of Solo: you see every change to OM336 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in